Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins

Cytochrome P450 and ischemic heart disease: current concepts and future directions

(2013) Andrew Rowland et al.   Expert Opinion on Drug Metabolism & Toxicology

The UDP-glucuronosyltransferases: Their role in drug metabolism and detoxification

(2013) Andrew Rowland et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport

(2013) Catherine K. Yeung et al.   KIDNEY INTERNATIONAL

Effect of uremic serum and uremic toxins on drug metabolism in human microsomes

(2013) Donna A. Volpe et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY

Uremic toxins inhibit renal metabolic capacity through interference with glucuronidation and mitochondrial respiration

(2012) H.A.M. Mutsaers et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Characterization of Niflumic Acid as a Selective Inhibitor of Human Liver Microsomal UDP-Glucuronosyltransferase 1A9: Application to the Reaction Phenotyping of Acetaminophen Glucuronidation

(2011) J. O. Miners et al.   DRUG METABOLISM AND DISPOSITION

Oral supplementation with sulodexide inhibits neo-angiogenesis in a rat model of peritoneal perfusion

(2011) A. Pletinck et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Novel method for simultaneous determination of p-cresylsulphate and p-cresylglucuronide: clinical data and pathophysiological implications

(2011) N. Meert et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Warning: the unfortunate end of p-cresol as a uraemic toxin

(2011) R. Vanholder et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Hepatic Clearance, but Not Gut Availability, of Erythromycin Is Altered in Patients With End-Stage Renal Disease

(2010) H Sun et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Delayed Elimination of SN-38 in Cancer Patients with Severe Renal Failure

(2010) K.-i. Fujita et al.   DRUG METABOLISM AND DISPOSITION

In Vitro-In Vivo Extrapolation Predicts Drug-Drug Interactions Arising from Inhibition of Codeine Glucuronidation by Dextropropoxyphene, Fluconazole, Ketoconazole, and Methadone in Humans

(2010) P. Raungrut et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Inhibitory effects of uraemic toxins 3-indoxyl sulfate andp-cresol on losartan metabolismin vitro

(2010) Masayuki Tsujimoto et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping andin vitro–in vivoextrapolation of drug clearance and drug-drug interaction potential

(2009) John O. Miners et al.   DRUG METABOLISM REVIEWS

Free Drug Metabolic Clearance in Elderly People

(2008) Jennifer M Butler et al.   CLINICAL PHARMACOKINETICS

The "Albumin Effect" and Drug Glucuronidation: Bovine Serum Albumin and Fatty Acid-Free Human Serum Albumin Enhance the Glucuronidation of UDP-Glucuronosyltransferase (UGT) 1A9 Substrates but Not UGT1A1 and UGT1A6 Activities

(2008) A. Rowland et al.   DRUG METABOLISM AND DISPOSITION

The "Albumin Effect" and in Vitro-in Vivo Extrapolation: Sequestration of Long-Chain Unsaturated Fatty Acids Enhances Phenytoin Hydroxylation by Human Liver Microsomal and Recombinant Cytochrome P450 2C9

(2008) A. Rowland et al.   DRUG METABOLISM AND DISPOSITION